Front cover image for Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial

Peer-reviewed

Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial

Viral N Shah, Amer Al-Karadsheh, Cathy Barnes, Jose Mandry, Samer Nakhle, Karin Wernicke-Panten, Daniel Kramer, Wolfgang Schmider, Suzanne Pierre, Lenore Teichert, Baerbel Rotthaeuser, Bhaswati Mukherjee, Timothy S Bailey
To assess whether multiple switches between SAR341402 biosimilar insulin aspart (SAR-Asp) and the insulin aspart reference product (NovoLog; NN-Asp) leads to equivalent pharmacokinetic (PK) exposure compared with continuous use of NN-Asp in adults with type 1 diabetes (T1D)
Article, 2024